| Autor: |
Cristina ML; Department of Health Sciences, University of Genoa, Via Pastore 1, 16132 Genoa, Italy.; Hospital Hygiene Unit, E.O. Ospedali Galliera, 16128 Genova, Italy., Spagnolo AM; Department of Health Sciences, University of Genoa, Via Pastore 1, 16132 Genoa, Italy.; Hospital Hygiene Unit, E.O. Ospedali Galliera, 16128 Genova, Italy., Sartini M; Department of Health Sciences, University of Genoa, Via Pastore 1, 16132 Genoa, Italy.; Hospital Hygiene Unit, E.O. Ospedali Galliera, 16128 Genova, Italy., Carbone A; Department of Health Sciences, University of Genoa, Via Pastore 1, 16132 Genoa, Italy., Oliva M; Department of Health Sciences, University of Genoa, Via Pastore 1, 16132 Genoa, Italy., Schinca E; Department of Health Sciences, University of Genoa, Via Pastore 1, 16132 Genoa, Italy.; Hospital Hygiene Unit, E.O. Ospedali Galliera, 16128 Genova, Italy., Boni S; Infectious Disease Unit, Galliera Hospital, 16128 Genoa, Italy., Pontali E; Infectious Disease Unit, Galliera Hospital, 16128 Genoa, Italy. |
| Abstrakt: |
Candida auris has become a major concern in critical care medicine due to the increasing number of immunocompromised patients and candidiasis is the most frequent cause of fungal infections. C. auris and other fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year. In immunocompromised patients, infections can quickly become severe, causing wound infections, otitis and candidemia, resulting in high morbidity and mortality. The clinical presentation of C. auris is often non-specific and similar to other types of systemic infections; in addition, it is harder to identify from cultures than other, more common types of Candida spp. Some infections are particularly difficult to treat due to multi-resistance to several antifungal agents, including fluconazole (and other azoles), amphotericin B and echinocandins. This entails treatment with more drugs and at higher doses. Even after treatment for invasive infections, patients generally remain colonized for long periods, so all infection control measures must be followed during and after treatment of the C. auris infection. Screening patients for C. auris colonization enables facilities to identify individuals with C. auris colonization and to implement infection prevention and control measures. This pathogenic fungus shows an innate resilience, enabling survival and persistence in healthcare environment and the ability to rapidly colonize the patient's skin and be easily transmitted within the healthcare setting, thus leading to a serious and prolonged outbreak. |
